Does Entresto Improve Ejection Fraction in Your Heart?

If you’ve ever heard someone say, “My ejection fraction went up!” and everyone in the room nodded like that sentence
explained the entire universewelcome. You’re in the right place.

Entresto (sacubitril/valsartan) is a major heart-failure medication, and one of the most common questions is whether
it can actually improve ejection fraction (EF)the percentage of blood your left ventricle pumps out with each beat.
The short version: for many people with heart failure with reduced ejection fraction (HFrEF), EF can improve over time on Entresto,
but it’s not a magic elevator button, and EF is only one part of the “Is my heart doing better?” story.

Let’s break it down with real evidence, clear explanations, and just enough humor to keep your heart rate
from skyrocketing (that’s a different diagnosis).

Entresto 101: What It Is and Why It’s Different

Entresto is a combo medication: sacubitril + valsartan. Together, they form an ARNI:
angiotensin receptor–neprilysin inhibitor.

What the two halves do

• Valsartan blocks the angiotensin II receptor (similar to an ARB), helping relax blood vessels and reduce strain on the heart.
• Sacubitril inhibits neprilysin, an enzyme that breaks down helpful “natriuretic peptides.” Keeping those peptides around longer can
  support blood vessel relaxation, sodium/water balance, and lower cardiac stress signals.

In plain English: Entresto helps dial down the hormonal “pressure cooker” that makes heart failure worse, while boosting the body’s
natural “relax, unload, and protect” signals. That combination is why researchers pay attention not only to symptoms and hospitalizations,
but also to heart structure and function over time.

Ejection Fraction: The Quick, Non-Scary Explanation

Ejection fraction (EF) is the percentage of blood the left ventricle ejects with each contraction.
It’s often measured by an echocardiogram (ultrasound of the heart). EF is useful, but it isn’t a full biography of your heart.
Think of it like a credit score: important, but it doesn’t tell the whole story of your life choices.

Common EF categories (adult)

• Normal: often around 55%–60% (ranges vary by source and lab)
• Mildly reduced: about 41%–49%
• Reduced (HFrEF): usually ≤40%
• Preserved (HFpEF): typically ≥50% (you can still have heart failure with a “normal” EF)

A key point: EF can bounce around depending on hydration, blood pressure, heart rhythm, the imaging method, and even who’s reading the scan.
So when you’re tracking EF changes, it’s best to compare studies done in a similar wayideally at the same lab.

So… Does Entresto Improve Ejection Fraction?

For many people with HFrEF, EF can improve after starting Entresto, especially over months of consistent therapy.
The reason isn’t that Entresto “forces” EF upward like a video game power-up. Instead, it can support
reverse remodelinga fancy term for the heart becoming less stretched and more efficient again.

The strongest evidence: heart remodeling studies

The PROVE-HF study followed people with HFrEF treated with sacubitril/valsartan and looked at changes in biomarkers and echocardiogram measurements over a year.
Results showed improvements in measures of cardiac structure and function, and EF increased on average over time in the study population.
Importantly, reductions in NT-proBNP (a heart-stress biomarker) were associated with improvements in echo measures.

Translation: when the heart’s “distress signal” quieted down, the heart often looked and performed better on imagingEF included.
That doesn’t guarantee every individual sees the same jump, but it supports a real physiological pathway for improvement.

The big outcomes trials: fewer deaths and hospitalizations (EF is part of the context)

In the landmark PARADIGM-HF trial, sacubitril/valsartan outperformed enalapril for reducing cardiovascular death and heart-failure hospitalization
in HFrEF. PARADIGM-HF wasn’t primarily designed as an “EF improvement” trial, but it established Entresto as a foundation therapy because people did better
in the outcomes that matter most: living longer and staying out of the hospital.

Why does that matter for EF? Because EF is meaningful, but it’s not the only target. A medication can improve survival and reduce hospitalizations even if EF changes
are modestor variableacross individuals.

Hospital-start data: the heart stress marker drops early

In PIONEER-HF (patients hospitalized for acute decompensated HFrEF), starting sacubitril/valsartan after stabilization produced a greater reduction in NT-proBNP than enalapril.
NT-proBNP is not EF, but it’s often used as a “how hard is the heart struggling?” signal. Lowering it can be an early sign that the heart is under less strain.

Who’s Most Likely to See EF Improve on Entresto?

EF improvement is most commonly discussed in HFrEF, especially in people whose EF is low because the heart’s pumping chamber has become enlarged and weak
(often called “dilated” patterns). But the real world is messy (like a junk drawer), and response can vary.

Factors that can make EF improvement more likely

• Consistent use over time: remodeling tends to be a months-long story, not an overnight plot twist.
• Guideline-directed “team therapy”: Entresto is often used alongside beta-blockers, MRAs, and SGLT2 inhibitorstherapies that also improve outcomes in HFrEF.
• Cause of heart failure: Some causes (like certain non-ischemic cardiomyopathies) may show more EF recovery than others, but individuals vary widely.
• Blood pressure and tolerability: being able to stay on therapy and up-titrate as tolerated is often part of achieving best effect (always clinician-guided).
• Fewer ongoing injuries: continued uncontrolled high blood pressure, untreated sleep apnea, heavy alcohol use, or ongoing ischemia can keep the heart from recovering.

One more truth that’s hard but useful: sometimes EF improves a lot and symptoms improve a little; sometimes symptoms improve first and EF lags behind.
The heart does not always read the script.

How Long Does It Take to See EF Changes?

Many clinicians think in terms of months. Remodeling changes have been observed by around 6 months in studies and can continue through 12 months.
In real life, cardiology teams often repeat imaging after a period of medication optimizationcommonly around 3–6 months or longerdepending on the situation.

If your EF is rechecked too early, you might miss the “slow improvement” that happens as the heart remodels. If it’s rechecked too often, you might end up chasing normal measurement wiggles.
(Yes, your heart can have “good days” and “meh days,” just like the rest of us.)

What About HFpEF or Mildly Reduced EF?

Heart failure isn’t one-size-fits-all. In HFpEF (preserved EF), the issue is often stiffness and filling problems rather than weak squeezing.
Trials like PARAGON-HF examined sacubitril/valsartan in HFpEF and did not meet the primary endpoint overall, though some subgroup patterns suggested potential benefit closer to the “below normal” EF range.

The FDA labeling for Entresto notes benefits are most clearly evident in patients with LVEF below normal.
This wording matters: it acknowledges that the line between “reduced” and “not reduced” isn’t a brick wall.
Still, EF improvement isn’t the main reason Entresto is prescribed in HFpEF-like scenarios; the goal is symptom control and risk reduction where evidence supports it.

How Doctors Decide Whether Entresto Is “Working”

EF is one checkpoint, not the entire road trip. Clinicians typically evaluate:

• Symptoms: less shortness of breath, better stamina, less swelling, easier daily activity
• Hospitalizations: fewer flare-ups requiring ER visits or admission
• Vitals and exam: blood pressure, weight trends, fluid status
• Labs: kidney function and potassium; sometimes NT-proBNP trends
• Imaging: EF plus heart size/volumes and valve pressures when relevant

It’s totally possible for someone to feel better before EF changes show upor for EF to improve while the person still needs time to rebuild stamina.
Hearts are hardworking, but they don’t love being rushed.

Safety Notes That Matter (Because Your Heart Isn’t the Only Organ Involved)

Entresto is widely used, but it’s not a “take it and forget it” medication. It can affect blood pressure, kidney function, and potassium levels.
Serious allergic swelling (angioedema) is rare but important.

Common or notable risks to know

• Low blood pressure (hypotension): dizziness, lightheadedness, feeling faint
• High potassium (hyperkalemia): can affect heart rhythm; usually detected by labs
• Kidney function changes: monitored with blood tests
• Angioedema: swelling of face/lips/tongue/throatrequires urgent attention
• Pregnancy warning: drugs affecting the renin-angiotensin system can harm a developing fetus

A crucial detail if switching therapies: Entresto should not be taken together with an ACE inhibitor, and a washout period is required when switching
(this is a safety rule designed to reduce angioedema risk). Always follow a clinician’s plan for transitions.

Specific Examples: What EF Improvement Can Look Like

Every patient is different, but here are realistic, simplified examples that mirror common clinical patterns:

Example 1: HFrEF with gradual recovery

A person starts with an EF around 30%. After several months of consistent, clinician-guided heart-failure therapy (including Entresto and other standard meds),
they feel less breathless walking up stairs. A follow-up echo later shows EF around 38–40% and smaller left ventricular volumes.
That’s not “instantly normal,” but it’s meaningful improvementespecially if it matches fewer symptoms and fewer hospital visits.

Example 2: EF improves, but stamina needs time

Another person’s EF improves from the mid-20s to the mid-30s after months of therapy. They’re thrilleduntil they realize their muscles are still deconditioned.
Cardiac rehab, nutrition, sleep, and gradual activity rebuilding become the next chapter. The heart is improving, but the body needs to catch up.

Example 3: EF doesn’t move much, but life does

Someone’s EF changes only slightly, but they stop landing in the hospital every few months. They can do more daily activities without panic-breathing.
In heart failure care, that counts as a big win, even if EF doesn’t throw a parade.

If EF Improves, Can You Stop Heart Failure Meds?

This is a common trap questionlike asking, “If I clean my room once, can I stop cleaning forever?”

Many clinicians recommend continuing guideline-based therapy even if EF improves into a better range, because stopping can allow heart failure to worsen again.
There’s a name for this situation: heart failure with improved ejection fraction (sometimes called HFimpEF), where EF rises above the reduced range
after having been low. “Improved” doesn’t necessarily mean “cured.”

If you’re tempted to change medications because you feel better or your EF improved, that’s an important conversation for your cardiology teamnot a solo experiment.

Questions to Ask Your Clinician (So You Leave With Answers, Not Just Vibes)

• What type of heart failure do I have (HFrEF, HFmrEF, HFpEF), and what’s my current EF?
• What’s our goal for therapysymptoms, preventing hospitalizations, improving remodeling, all of the above?
• When should we recheck my echocardiogram, and what changes are we hoping to see?
• What side effects should I watch for, and what labs are we monitoring?
• How does Entresto fit with my other meds (beta-blocker, MRA, SGLT2 inhibitor, diuretics)?

Lived Experiences: What People Often Notice on the Entresto Journey (About )

People don’t experience Entresto as a single dramatic moment. It’s usually more like a series of small “huh, that’s different” observations that add up.
Many describe the first weeks as a period of adjustmentespecially if blood pressure runs on the lower side.
A common early story is standing up too quickly and feeling a little woozy, then learning (with guidance from the care team) how to manage timing, hydration,
and other medications that also affect blood pressure. Some people joke that their heart medicine taught them manners: no more launching out of bed like a movie hero.

Over the next couple of months, the “wins” people mention are often practical. It might be realizing they can carry groceries without stopping to negotiate
with their lungs. Or noticing their shoes fit more comfortably because swelling is better controlled (often with the broader treatment plan, not just one pill).
Some people say sleep improves when nighttime breathing feels less strainedthough sleep issues can have many causes, so clinicians often look at the whole picture,
including possible sleep apnea.

Clinic visits become part of the rhythm. People may get used to periodic blood tests to check potassium and kidney function, and they learn that these labs aren’t
“bad news”they’re guardrails. A lot of patients say it feels empowering to understand what’s being monitored and why.
For some, the first time NT-proBNP drops significantly (if it’s being followed) feels like seeing the scoreboard change: “Okay, something is happening.”

Then comes the echothe moment many people treat like a report card. Some walk in hoping for a miracle number.
Others are nervous because they feel better and don’t want the test to contradict that. When EF improves, people often describe a mix of relief and disbelief,
like they’re waiting for someone to say, “Just kidding!” When EF doesn’t improve much, it can feel discouraging, and clinicians often have to reframe:
“Let’s look at symptoms, stability, and hospitalizations too.” That reframing matters because heart failure care is about outcomes and quality of life,
not just a single percentage.

Many caregivers experience their own version of the journeywatching for swelling, tracking weight changes if asked by the care team,
noticing whether a loved one can talk without pausing for breath. Caregivers often say the most meaningful improvements are small everyday moments:
a normal conversation, a short walk, a laugh that doesn’t turn into coughing. Those are hard to measure, but they’re real.

Across stories, one theme repeats: when Entresto is part of a well-rounded plan (meds, follow-ups, lifestyle supports, sometimes cardiac rehab),
improvements often feel gradual but genuinelike the heart is slowly getting back into a healthier routine.
Not everyone’s EF rises dramatically, but many people find that life becomes more manageable, and that’s a victory worth counting.

The Bottom Line

YesEntresto can improve ejection fraction in many people with HFrEF, likely by supporting reverse remodeling and reducing heart stress over time.
The best evidence shows improvements in heart structure/function measures and average EF increases in remodeling-focused studies, while large outcome trials confirm
Entresto reduces cardiovascular death and heart-failure hospitalizations in HFrEF.

But EF isn’t the whole story. The “real win” is usually a combination of feeling better, staying out of the hospital, and protecting the heart long-term.
If you’re taking Entresto (or considering it), the smartest move is to treat EF as one valuable data pointand work with your clinician on the full plan that supports your heart.

Medical note: This article is for general education and is not personal medical advice. Medication decisions, transitions, and monitoring should be guided by a licensed clinician.